OptiBiotix Health plc, the life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and cardiovascular health, is now in a pivotal position.
Having delivered a five-fold increase in H1 2020 revenues on the comparable period, the Group’s scalable business model is positioned to capture long-term growth from a portfolio of highly protected and proven products through licensing, royalties and distribution agreements with multiple international partners.
With the rising incidence of lifestyle-related conditions and expanding geriatric populations seen as the principal demand drivers for nontoxic human microbiome therapeutics as an alternative route for tackling such endemic healthcare challenges, one research institute projects a sector CAGR of 22.6%Â between 2017 to 2025 in a marketplace that, although presently dominated by North America continues to expand rapidly in both Europe and Asia.
Despite the uncertainty the Pandemic has injected into the global economic environment, OptiBiotix is expected to capture this market opportunity through the continued expansion of its range of applications, products and territories.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to OptiBiotix Health plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.
